S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
NASDAQ:ELEV

Elevation Oncology Stock Forecast, Price & News

$7.96
-0.33 (-3.98 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.96
$8.48
50-Day Range
$7.51
$12.98
52-Week Range
$7.38
$16.22
Volume
9,894 shs
Average Volume
60,880 shs
Market Capitalization
$184.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ELEV News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.


About Elevation Oncology

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELEV
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$184.88 million
Next Earnings Date
11/11/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

407th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

58th out of 197 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Elevation Oncology (NASDAQ:ELEV) Frequently Asked Questions

Is Elevation Oncology a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Elevation Oncology stock.
View analyst ratings for Elevation Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Elevation Oncology?

Wall Street analysts have given Elevation Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Elevation Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Elevation Oncology?

Elevation Oncology saw a increase in short interest in September. As of September 30th, there was short interest totaling 138,700 shares, an increase of 4,234.4% from the September 15th total of 3,200 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.0% of the shares of the company are sold short.
View Elevation Oncology's Short Interest
.

When is Elevation Oncology's next earnings date?

Elevation Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Elevation Oncology
.

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its quarterly earnings results on Thursday, August, 12th. The company reported ($4.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $4.46.
View Elevation Oncology's earnings history
.

What price target have analysts set for ELEV?

4 brokerages have issued 12-month price targets for Elevation Oncology's stock. Their forecasts range from $12.10 to $27.00. On average, they expect Elevation Oncology's share price to reach $20.78 in the next twelve months. This suggests a possible upside of 161.0% from the stock's current price.
View analysts' price targets for Elevation Oncology
or view top-rated stocks among Wall Street analysts.

Who are Elevation Oncology's key executives?

Elevation Oncology's management team includes the following people:
  • Dr. Shawn Leland Pharm.D., R.Ph., Founder, Pres, CEO & Director (Age 37, Pay $452.74k)
  • Mr. Joseph J. Ferra Jr., Chief Financial Officer (Age 45)
  • Ms. Tammy Furlong CPA, P.M.P., VP of Fin. & Accounting and Sec.
  • Mr. Brian Sullivan, VP of Corp. Devel.

When did Elevation Oncology IPO?

(ELEV) raised $1 billion in an IPO on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

What is Elevation Oncology's stock symbol?

Elevation Oncology trades on the NASDAQ under the ticker symbol "ELEV."

When does the company's lock-up period expire?

Elevation Oncology's lock-up period expires on Wednesday, December 22nd. Elevation Oncology had issued 6,250,000 shares in its public offering on June 25th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Elevation Oncology?

Shares of ELEV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Elevation Oncology's stock price today?

One share of ELEV stock can currently be purchased for approximately $7.96.

How much money does Elevation Oncology make?

Elevation Oncology has a market capitalization of $184.88 million.

How many employees does Elevation Oncology have?

Elevation Oncology employs 8 workers across the globe.

What is Elevation Oncology's official website?

The official website for Elevation Oncology is www.elevationoncology.com.

How can I contact Elevation Oncology?

The company can be reached via phone at 716-371-1125 or via email at [email protected]elevationoncology.com.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.